Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony T Reder

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Epilepsy & Behavior : E&B|December 24, 2013
Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsyDavid Victorson, Jose E Cavazos, Gregory L Holmes, et al.
BMJ Open|December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyDouglas S Goodin, George C Ebers, Gary Cutter, et al.
Neurology and Therapy|January 11, 2024
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary PerspectivesMark S Freedman, Patricia K Coyle, Kerstin Hellwig, et al.
Physiological Reports|December 26, 2024
Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosisBrooks A Hibner, Natalia S Lima, Sara R Sherman, et al.
Epilepsy & Behavior : E&B|February 14, 2018
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsyAhmad Daif, Rimas V Lukas, Naoum P Issa, et al.
JAMA Neurology|November 25, 2014
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementAnn M Arvin, Jerry S Wolinsky, Ludwig Kappos, et al.
BMC Neurology|July 18, 2012
Brief International Cognitive Assessment for MS (BICAMS): international standards for validationRalph H B Benedict, Maria Pia Amato, Jan Boringa, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
CNS Drugs|March 20, 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying TherapiesAnthony T Reder, Diego Centonze, Maria L Naylor, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Epilepsy & Behavior : E&B|December 24, 2013
Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsyDavid Victorson, Jose E Cavazos, Gregory L Holmes, et al.
BMJ Open|December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyDouglas S Goodin, George C Ebers, Gary Cutter, et al.
Neurology and Therapy|January 11, 2024
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary PerspectivesMark S Freedman, Patricia K Coyle, Kerstin Hellwig, et al.
Physiological Reports|December 26, 2024
Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosisBrooks A Hibner, Natalia S Lima, Sara R Sherman, et al.
Epilepsy & Behavior : E&B|February 14, 2018
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsyAhmad Daif, Rimas V Lukas, Naoum P Issa, et al.
JAMA Neurology|November 25, 2014
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementAnn M Arvin, Jerry S Wolinsky, Ludwig Kappos, et al.
BMC Neurology|July 18, 2012
Brief International Cognitive Assessment for MS (BICAMS): international standards for validationRalph H B Benedict, Maria Pia Amato, Jan Boringa, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
CNS Drugs|March 20, 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying TherapiesAnthony T Reder, Diego Centonze, Maria L Naylor, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Pageof 9